Breast-cancer drug letrozole picks up where tamoxifen leaves off. But we don't know who stands to benefit the most from this follow-up approach.
Runowicz, Carolyn D.
; 9(12): 4-5, 2003 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-14679962
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Aromatase inhibitors in breast cancer prevention.
Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
When to start an aromatase inhibitor: now or later?
Prescribing extended adjuvant letrozole.
Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.
Another pill for breast cancer prevention.
Breast cancer chemoprevention: little progress in practice?
Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Letrozole in breast cancer.